Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel. Show more
2 UNIVERSITY PLAZA, HACKENSACK, NJ, UNITED STATES, 07601, Hackensack, NJ, 07601, USA
Market Cap
184.5M
52 Wk Range
$1.48 - $3.19
Previous Close
$2.22
Open
$2.24
Volume
1,075,616
Day Range
$2.22 - $2.36
Enterprise Value
147.4M
Cash
27.42M
Avg Qtr Burn
-10.4M
Insider Ownership
3.88%
Institutional Own.
22.08%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details Genetic disorder, Rare genetic disease | Approved Quarterly sales | |
Elelyso® (taliglucerase alpha) Details Genetic disorder, Rare genetic disease | Approved Quarterly sales | |
PRX-115 Details Chronic refractory gout | Phase 2 Data readout | |
PRX-119 (DNase I Enzyme) Details Rare Renal, NETs-Related Diseases | IND Submission | |
Alidornase alfa (PRX-110) Details Genetic disorder, Rare genetic disease, Cystic fibrosis | Failed Discontinued | |
OPRX-106 Details Inflammatory disease, Bowel disorder | Failed Discontinued |
